Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
23 March 2022 | Story André Damons | Photo UFS Photo Archive
Prof Matsabisa
Prof Motlalepula Matsabisa is a professor and Director of Pharmacology at the University of the Free State (UFS)

The Department of Pharmacology at the University of the Free State (UFS) and FARMOVS have teamed up to conduct the first South African Health Products Regulatory Authority (SAHPRA)-approved multicentre controlled clinical trial of a plant-based product, PHELA, on mild to moderate COVID-19 patients.  

According to Prof Motlalepula Matsabisa, professor and Director of Pharmacology at UFS, it is anticipated that the trial will start in early April with each patient being on treatment for 28 days.

“The main purpose of the clinical trial is to confirm that the product can treat COVID-19 and be registered as a medication for this indication. We believe the medication works as an immune modulator to modulate the cytokine storm due to COVID-19 and also restores and normalises the patient’s immune system. We plan to have 250 patients who suffer from mild to moderate COVID-19,” explains Prof Matsabisa. 

This pivotal study, he says, is based on the modification of the World Health Organisation (WHO) Master protocol for clinical trials. The use of FARMOVS, a wholly owned clinical research company of the UFS Bloemfontein campus, for this clinical trial was to implement the collaborative initiatives between UFS and FARMOVS on clinical research, training, and other research projects.

What is PHELA?

Prof Matsabisa, deputy president of the South African Society for Basic and Clinical Pharmacology Society (SASBCP), says the development of PHELA has been under stringent scientific scrutiny for its safety in both preclinical and clinical research. The efficacy of PHELA as both an immune modulator and an anti-SARS-COV-2 has been proven in vitro and in vivo with reproducible results conducted by three independent research institutions and a science council.
The Department of Pharmacology and FARMOVS are collaborating on a number of studies to advance clinical research on African Traditional Medicines (ATM).

On the use of PHELA, Prof Matsabisa explains: “PHELA is a herbal product made of four medicinal plants. Traditionally PHELA has been claimed for use for a historical disease called muyaga, but recently has been scientifically tested and found effective as an immune modulator and benefiting persons with a compromised immune system.
“The PHELA plants are found in most provinces of South Africa and we have cultivated them to control their growth to produce quality raw materials.” 

“The SAHPRA-approved clinical trial will be conducted in the Eastern Cape, Northern Cape and Gauteng. The clinical trial will be conducted by a complement of medical staff and clinicians with vast experience of many active years of clinical trials.
 
“The study, we believe, is a benchmark for all future traditional medicines clinical trial protocols and studies. The studies are expected to start immediately after the product batch manufacturing of the study product, PHELA, is completed and this will be within a month’s time. “A lot of good scientific preclinical safety and efficacy research has gone into the development of the study product for it to reach this stage.

“The efficacy studies have shown convincingly that PHELA is an immune reconstitution product and does have an effect in killing the SARS-COV-2 virus and most of its variants.  PHELA efficacy, therefore, needs to be confirmed through randomised controlled multicentre clinical trials in COVID-19 patients,” Prof Matsabisa says.

Medicinal plants have previously been used to eradicate life-threatening viruses 

Although medicinal plants have been used to combat previous pandemics such as the Spanish flu, avian influenza and others, we still believe rigorous control and efficacy thereof is still to be supported by scientific research and development, says Prof Matsabisa. 

Prof Matsabisa, the current chairperson of the World Health Organisation’s (WHO) Regional Expert Advisory Committee on Traditional Medicines (REACT), adds: “We have better technologies and resources now, which is why we should take the next step in research to promote consumer safety and to offer them effective alternatives. We do the science to aid in building the herbal industry and develop sustained consumer confidence in traditional medicines. 

Africa should lead the way to a healthier future for all
“My vision is for Africa to share our valuable resources with the world by developing, and distributing world-class medicinal solutions. We should develop and strengthen the pharmaceutical local production of well-researched, quality, safe and efficacious African traditional medicines as commercial products. We are more than capable of doing so and now is the time to do it. Numerous discussions have taken place where other African countries will join South Africa in conducting multicentre studies in clinical trials for traditional medicines. 

“We need to develop or create, based on this current collaborative work with partners like FARMOVS, health centres with a strong focus on African medicines, health products and healing, but in a very strong collaborative initiative with other health systems”, concludes Prof Matsabisa.

Prof Matsabisa was recently awarded a Visiting Professorship at the Beijing University of Chinese Medicine (BUCM) in Beijing, China. He was also recommended to Naledi Pandor, Minister of International Relations and Cooperation, to be part of the India, Brazil and South Africa (IBSA) working group in traditional medicine through his participation in the national department of health technical committee on traditional medicines where he has been appointed by the Minister of Health, Dr Joe Phaahla.

News Archive

UFS students should register like this
2004-12-15

Student activities on the main campus of the University of the Free State (UFS) will start next year when first-time entering first-year students will be welcomed by the Rector and Vice-Chancellor of the UFS, Prof Frederick Fourie, on 15 January at 11:00 in the Callie Human Centre on campus.

“The registration process will start on 17 January 2005 when first-time entering first-year students, who applied for admission before 30 November 2005, will start registering. These students may register until 21 January 2005 according to a programme,” said Mr Vernon Collett, Registrar: Academic Student Services at the UFS.

Senior undergraduate students may register from 22-29 January 2005 and postgraduate students, first-time entering first-year students and other students who applied for admission after 30 November 2004 until 15 January 2005, may register from 31 January- 4 February 2005 according to a programme.

According to Mr Collett postgraduate students who applied for admission from 15 January- 11 February 2005, may register according to a programme from 7-11 February 2005. Students who want to change their field of study or want to amend their modules, may do it during this period.

“To ensure an orderly registration process, strict adherence to the registration programme will be maintained,” said Mr Collett.

Applications for the Career Preparation Programme (CPP) close on 21 January 2005 en those for upgrading courses in Education, will close on 2 February 2005.

“Pipeline students from Vista must register on the UFS’s Vista campus on the dates already mentioned and first-year students from Vista must register on the UFS’s main campus,” said Mr Collett.

All registrations will take place daily from 08:00 in the Callie Human Centre on the main campus.

According to Mr Collett a variety of services will be available to students in the Callie Human Centre during the registration – among others advice on bursaries, loans, staff and council bursaries, enquiries for international students, information on class and room tables, student cards, vehicle permits etc.

At the Qwaqwa campus all first-time entering first-year students must report on 17 January 2005, after which the registration of these students will take place according to a specific programme. Application for admission to this campus close on 1 February 2005. First-time entering first-year students will be welcomed by the Rector and Vice-Chancellor of the UFS, Prof Frederick Fourie, on 22 January 2005 at 11:00 in the Nelson Mandela Hall on campus.

Lectures at the UFS’s main campus as well as the Vista- and Qwaqwa-campusses will commence on 31 January 2005.

Prospective students who want to apply or who have any enquiries can call (051) 401-3000 or visit the UFS web site late in December 2004 at www.uovs.ac.za.

A complete registration programme for first-time entering first-year students who registered before 30 November 2004 will appear in Volksblad of 29 Desember 2004.

      Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
15 December 2004

 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept